Stay updated with breaking news from Roivant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Wolfe Research started coverage on shares of Roivant Sciences (NASDAQ:ROIV – Free Report) in a research note published on Thursday, Marketbeat reports. The brokerage issued an outperform rating and a $17.00 price target on the stock. A number of other equities analysts have also recently commented on ROIV. Deutsche Bank Aktiengesellschaft started coverage on shares […]
Silverarc Capital Management LLC purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 100,000 shares of the company’s stock, valued at approximately $1,168,000. A number of other institutional investors have also recently […]
Tourlite Capital Management, an investment management firm, released its fourth quarter 2023 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 1.1% for Q4 2023 and 8.8% for the year. Since its inception in April 2022, the fund returned 14.3% compared to 8.4%, and 0.5% returns for the S&P […]
Investigation of RVT-2001 will be discontinued following an insufficient display of benefit in patients with myelodysplastic syndrome.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) had its target price reduced by stock analysts at HC Wainwright from $18.00 to $17.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 54.26% from the company’s […]